Multiple endocrine neoplasia [MEN] type IIA
ICD-10 E31.22 is a billable code used to indicate a diagnosis of multiple endocrine neoplasia [men] type iia.
Multiple endocrine neoplasia type IIA (MEN IIA) is a hereditary syndrome characterized by the development of tumors in multiple endocrine glands. The most common manifestations include medullary thyroid carcinoma, pheochromocytoma, and primary hyperparathyroidism. Patients may also experience growth abnormalities due to hormonal imbalances, particularly during puberty, as the condition can lead to precocious puberty or delayed growth. Polyglandular dysfunction is a hallmark of MEN IIA, where multiple glands are affected, leading to a complex interplay of symptoms. Thymus disorders may also be present, as the thymus gland can be involved in the immune response, which is often altered in patients with MEN syndromes. The diagnosis is typically made through genetic testing and clinical evaluation, with a focus on family history and the presence of associated tumors. Early detection and management are crucial to prevent complications associated with the tumors and hormonal imbalances.
Thorough documentation of hormonal levels, imaging studies, and genetic testing results.
Patients presenting with symptoms of hyperparathyroidism, thyroid nodules, or adrenal tumors.
Endocrinologists must ensure all relevant endocrine glands are evaluated and documented.
Detailed pathology reports and treatment plans for tumors.
Management of medullary thyroid carcinoma or pheochromocytoma.
Oncologists should document tumor staging and treatment response.
Used when a biopsy is performed on a suspected tumor.
Pathology report must be included in the medical record.
Oncologists should ensure that all tumor types are accurately documented.
Common symptoms include hypercalcemia, thyroid nodules, hypertension due to pheochromocytoma, and symptoms related to hormonal imbalances such as growth abnormalities.
